Vericrest Private Wealth’s GSK GSK Stock Holding History

Vericrest Private Wealth’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,094	Closed	-$446K	–	43
2025 Q4	$446K	Buy	+9,094	New	+$424K	0.4%	32

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vericrest Private Wealth's GSK Position: Q1 2026 in Review

Vericrest Private Wealth sold out of GSK (GSK) in Q1 2026, closing a stake of 9,094 shares — an estimated $446K sold.

Vericrest Private Wealth first reported a position in GSK in Q4 2025 and held it in 1 quarter. The position peaked at $446K in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Vericrest Private Wealth reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Vericrest Private Wealth sold 9,094 GSK shares in Q1 2026, an estimated $446K.
Vericrest Private Wealth first reported a position in GSK in Q4 2025 and held it in 1 quarter.
Vericrest Private Wealth's GSK position peaked at $446K in Q4 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Vericrest Private Wealth's 13F filing for Q1 2026, filed 7 May 2026.